Pulmonary hypertension – a condition that not only affects millions worldwide but also claimed the life of legendary singer Natalie Cole. Today, we explore the battle against this life-altering disease.
In 2024, pulmonary hypertension is estimated to affect 1% of the global population. The condition, often marked by shortness of breath, fatigue, and chest pain, can lead to heart failure if left untreated. Natalie Cole, who passed away due to complications from this disease, is a reminder of its severity. But thanks to biotech innovations, there’s new hope.
From cutting-edge gene therapy research to digital health monitoring devices and AI-driven diagnostics, the landscape of treatment is rapidly evolving. Targeted therapies, precision medicine, and even emerging biomarker discoveries are paving the way for more personalized care. With early diagnosis and personalized treatment, patients are experiencing better outcomes.